
Rayca Precision enables faster discovery of therapies for hard-to-treat diseases using AI-driven design. The platform combines multi-omics analysis, in silico screenings, and predictive modeling to generate optimized drug candidates. It operates as a closed-loop system that feeds screening, in vitro testing, and preclinical data back into AI models and includes workflows for small molecules, peptides, peptidomimetics, biologics, and RNA-based drugs. Designed for biotech and pharma teams, the solution integrates bioinformatics, dynamic molecular simulations, high-resolution structural modeling, and epitope mapping to accelerate oncology, immunotherapy, and rare diseases pipelines.

Rayca Precision enables faster discovery of therapies for hard-to-treat diseases using AI-driven design. The platform combines multi-omics analysis, in silico screenings, and predictive modeling to generate optimized drug candidates. It operates as a closed-loop system that feeds screening, in vitro testing, and preclinical data back into AI models and includes workflows for small molecules, peptides, peptidomimetics, biologics, and RNA-based drugs. Designed for biotech and pharma teams, the solution integrates bioinformatics, dynamic molecular simulations, high-resolution structural modeling, and epitope mapping to accelerate oncology, immunotherapy, and rare diseases pipelines.